Current T cell manufacturing methods, adapted from other medical uses, face challenges like high costs, safety concerns, and inefficiencies, especially for leukemia patients. Automation is being developed to address these issues, but its success is still uncertain.
The proposed solution involves developing a closed-loop perfusion circuit for T cell engineering and expansion using two bioreactors: a small one for selection, activation, and transduction (Stage 1), and a larger one for expansion (Stage 2).
The goal of the project is to develop a superior process / platform for selection, activation and lentiviral vector transduction of human T-cells using perfusion bioreactor system
The project will enable continuous processing of T-cells in a closed environment and reduce process costs
Ling, J. & Milone, M., A Novel Perfusion-based 3D Bioreactor for Effective Selection, Activation, and Transduction of T-cells for Immunogene Therapy, NIIMBL Member Forum, Virtual, April 25, 2019.
Ling, J., A Novel Perfusion-Based Cell Manufacturing Platform for Regenerative Medicinee, RegenMed SA 2019 Annual Conference. San Antonio, TX, February 15, 2019.
Ling, J., A novel scalable manufacturing platform for T-cell activation and expansion in adoptiveT-cell therapy, ECI Advancing Manufacture of Cell and Gene Therapies VI, Coronado, CA, January 15, 2019.
Ling, J., “Technology Today” article, Southwest Research Institute, October 31, 2019.
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Southwest Research Institute
